Opus Genetics, Inc. IRD
4.31 USD +0.08 (+1.89%)
At closeNov 12, 2026, 6:27 AM EST
4.31 0.00 0.00%
Pre-market · Nov 12, 6:27 AM ET
4.13 Day range 4.52
1.70 52-week range 7.07
- YTD
- +114.43%
- 1 year
- +118.78%
News
benzinga.com RBC Capital Maintains Outperform on Opus Genetics, Raises Price Target to $11 RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $9 to $11.
benzinga.com HC Wainwright & Co. Maintains Buy on Opus Genetics, Raises Price Target to $14 HC Wainwright & Co. analyst Matthew Caufield maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $8 to $14.
zacks.com Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.12 per share a year ago.
benzinga.com Opus Genetics Q3 EPS $(0.46) Misses $(0.15) Estimate, Sales $1.137M Miss $1.959M Estimate Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.15) by 206.67 percent. This is a 84 percent decrease over losses of…
globenewswire.com Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Clearance of IND for…
globenewswire.com Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene…- benzinga.com FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early…
benzinga.com Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with
benzinga.com Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.- benzinga.com Opus Genetics Presents Clinical Findings From OPGx-BEST1 And OPGx-LCA5 Gene Therapy Programs At Retina In Rio 2026; Phase 3 Clinical Trial Dosing For OPGx-LCA5 Expected In Q4 Of 2026 OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical developmentNew…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
benzinga.com Crude Oil Jumps Over 3%; Core & Main Posts Upbeat Q2 Earnings U.S. stocks fell Wednesday as energy rose and discretionary slumped; Signet and Opus surged, while ServiceTitan plunged. Oil jumped 3.6%.
benzinga.com Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
benzinga.com Dow Tumbles 350 Points; Signet Jewelers Shares Jump Following Upbeat Q2 Earnings U.S. stocks fell Wednesday, led by a 350-point Dow drop. Signet surged on strong earnings; oil, gold and silver prices climbed.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding…
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In July Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com This Live Nation Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. See all changes, including upgrades and downgrades, on analyst ratings page.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session